Dr Ash Tewari to lead new Center for Prostate Cancer at NewYork-Presbyterian | health and fitness | Hindustan Times
Today in New Delhi, India
Dec 09, 2016-Friday
New Delhi
  • Humidity
  • Wind

Dr Ash Tewari to lead new Center for Prostate Cancer at NewYork-Presbyterian

health-and-fitness Updated: Jan 10, 2013 20:38 IST

Highlight Story

Dr Ashutosh K Tewari has been appointed the head of the newly-established Center for Prostate Cancer at NewYork-Presbyterian/Weill Cornell Medical Center, a comprehensive center dedicated to research into and the treatment of prostate cancer.

"We are pleased to establish the new Center for Prostate Cancer and are especially delighted that Dr. Ash Tewari, one of the world's top prostate cancer experts, will be leading this important new initiative. With his expertise and direction, we are poised to build upon our clinical strengths in prostate cancer and transform the health and lives of men and their loved ones," says Dr Steven J Corwin, CEO of NewYork-Presbyterian Hospital.

With its dual mission of delivering outstanding care to men with prostate cancer and conducting innovative, world-class research into this disease, the new Center for Prostate Cancer aims to ultimately improve the lives of patients in both the immediate and long term.

"There are many research programs that are directed toward advanced prostate cancer," notes Dr Tewari.

"My main focus is to not let anyone get to an advanced cancer stage; therefore, we will use a combination of imaging, genomics, surgery and novel therapies to augment our surgical results and thus improve survival while maintaining quality of life."

The center's clinical services include advanced screening and diagnostic methods, such as fusion biopsy, focal therapy for localized tumors, refined imaging techniques, open and robotic surgery, treatments for advanced prostate cancer and rehabilitation for urinary and sexual issues following treatment.

The Center for Prostate Cancer is committed to providing compassionate and personalized care for men with prostate cancer, the most common cancer in American men after skin cancer.

Dr Tewari's current research focus is on identifying genomic biomarkers for prediction of aggressive prostate cancer; this includes both single-cell and whole-genome sequencing.

In addition, he is investigating nerve-sparing strategies in robotic prostate cancer using an image-guided approach that preserves nerves that are important for sexual function and urinary continence.

Other research include the identification of molecular markers for prostate cancer, development of neuroprotective agents, advancement of ultrasound-guided biopsy techniques, racial disparities in prostate cancer, development of predictive models on prostate cancer survival, novel imaging techniques for surgery, and application of nanotechnology to the treatment of prostate cancer.